Business
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March
About this update from Precipio, Inc.
[{"type":"text","content":"This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms\nNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication’s authors: “Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings.” Ilan Danieli, CEO of Precipio, expanded on these findings. “Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression.” The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals. Key findings in the study highlight significant advantages of the assay 1. Multiple data points lead to better decision making The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time. 2. Full Quantification establishes a new standard Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse. Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) s...